If you have been reading about lyophilized powder and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-07-10. Numbers and descriptions here follow the published literature rather than marketing material.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Lyophilized thymosin alpha-1 is generally stored at or below minus twenty degrees Celsius, protected from moisture and light. Short-term handling at ambient temperature is possible for dry powder, but reconstituted solutions degrade faster and are usually kept at two to eight degrees Celsius with a defined expiry of days rather than weeks. Repeated freeze-thaw cycles should be avoided because they promote aggregation and loss of potency. Exact limits depend on the formulation and should follow the supplier's documentation.
Identity and purity are normally assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and truncation products. Mass spectrometry confirms molecular mass and detects modifications such as deamidation or oxidation. Amino acid analysis and peptide mapping provide additional sequence-level confirmation. For research material, a certificate of analysis typically reports these results together with water content and counter-ion identity, since the lyophilized powder is often supplied as an acetate or trifluoroacetate salt.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide, 28 residues | N-terminal fragment of prothymosin alpha |
| Molecular mass | About 3108 Da | Acetylated form |
| Isoelectric point | Near 4.2 | Acidic peptide |
| Appearance | White to off-white lyophilized powder | Common supplied form |
| Typical storage | -20 °C or below, dry | Solution stability is lower |
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
The lyophilized peptide is a white to off-white powder that dissolves freely in water and in aqueous buffers near neutral pH. Because the molecule carries a net negative charge under physiological conditions, saline and phosphate solutions are the usual vehicles, while strongly acidic media are avoided. Stock solutions are commonly divided into small aliquots so that repeated freezing and thawing can be limited, since cycling may encourage aggregation. Solubility in organic solvents is poor and those solvents are seldom used as primary diluents.
Recommended storage for the dry powder is a freezer near minus twenty degrees Celsius, kept desiccated and away from light. Once dissolved, the peptide is less stable and is usually held at two to eight degrees Celsius for short intervals or frozen for longer storage. Stability studies focus on the acetylated terminus and the disulfide linkage because those features define the intact molecule. Common degradation routes include cysteine oxidation, deamidation of asparagine or glutamine side chains, and slow formation of higher-molecular-weight species.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
== External links == Sharma, Vasundhara; Rao, Lingamallu Jagan Mohan (January 2014). "An Overview on Chemical Composition, Bioactivity and Processing of Leaves of Cinnamomum tamala". Critical Reviews in Food Science and Nutrition. 54 (4): 433–448. doi:10.1080/10408398.2011.587615. PMID 24236996. S2CID 46178245. Pandey, A. K.; Mishra, A. K.; Mishra, A. (22 December 2012). "Antifungal and antioxidative potential of oil and extracts derived from leaves of Indian spice plant Cinnamomum tamala". Cellular and Molecular Biology. 58 (1): 142–147. PMID 23273204. Indian bay-leaf page from Gernot Katzer's Spice Pages
Member, Genocide Survivors' Consultative Group, Holocaust Memorial Day Trust. For services to Genocide Education and Commemoration. Janis Lindy James. Founder, Good Egg Child Safety Campaign. For services to Children's Road Safety. Dr. Muhayman Jamil. Founder, Wheels and Wheelchairs. For services to People with Disabilities. Rizwan Javed. Station Assistant, MTR Elizabeth Line. For services to Vulnerable People. Thomas Andrew Raynes Jenkins. For services to the Forestry Sector. Professor Antony Johansen. Consultant Ortho-Geriatrician, Cardiff and Vale University Health Board. For services to Older People. Dr. Joseph John Galliano (Joseph Galliano-Doig). Director and Co-Founder, Queer Britain. For services to Heritage, to Charity, and to Diversity and Inclusion. Melanie Sharon John-Ross. Lately Service Director, Children's Social Care and Safeguarding. For services to Children and Families in Barnsley, South Yorkshire. Nicholas Edward Johnson. Co-Founder and Director, Market Operations. For services to Business and to the Food Sector. Professor Deborah Zerena Johnston. Deputy Vice-Chancellor, London South Bank University. For services to Stammering Recognition in Higher Education. The Reverend Derek James Johnston. Lead Chaplain, Belfast Health and Social Care Trust. For services to Chaplaincy and Well-Being during Covid-19. Ian Malcolm Jones. For services to Education in Merseyside. Dr. Peter Simpson Jones. Lead Specialist Advisor for Peatlands, Natural Resources Wales. For services to Welsh Peatlands and to the community in Wales. Shann Erin Jones.
The report that CMS requires labs to prominently display complaint posters instructing lab workers how to file anonymous complaints. In a July 2007 response to the GAO, CMS said that it lacked the legal authority to mandate labs to display posters. They plan to take several other steps to increase awareness of complaint processes including: (1) posting fact sheet on the CMS web site on complaint filing (2) adding information on filing complaints to the interpretive guidelines used by surveyors (3) adding complaints received by accrediting organizations to their complaints database and (4) reminding states and accrediting organizations by letter about the importance of complaints. CMS reported that it sent a letter about complaint tracking to accreditation organizations, exempt states, and professional laboratory organizations on November 30, 2007. According to CMS, this letter highlighted the importance of complaint tracking and filing, and encouraged the publication of compliant processes. CMS has also developed a CLIA Brochure on Complaints, which was being prepared for release as of September 2008. Once released, CMS anticipates posting the brochure on its website and printing copies for distribution to laboratories. We will continue to monitor the implementation of this recommendation. In 2009, the GAO recommended that CMS require all survey organizations to develop and require labs to prominently display posters instructing lab workers how to file anonymous complaints.
Sources: en.wikipedia.org
The condition has been described since ancient history. The Latinate term osteogenesis imperfecta was coined by Dutch anatomist Willem Vrolik in 1849; translated literally, it means "imperfect bone formation".
== Different types of Alpha Collagen == Collagen, type I, alpha 1 Collagen, type II, alpha 1 Collagen, type III, alpha 1 Collagen, type IV, alpha 1 Collagen, type V, alpha 1 Collagen, type VI, alpha 1 Collagen, type VII, alpha 1 Collagen, type VIII, alpha 1 Collagen, type IX, alpha 1 Collagen, type X, alpha 1 And many further types of alpha collagen are identified.
Bones serve a variety of mechanical functions. Together the bones in the body form the skeleton. They provide a frame to keep the body supported, and an attachment point for skeletal muscles, tendons, ligaments and joints, which function together to generate and transfer forces so that individual body parts or the whole body can be manipulated in three-dimensional space (the interaction between bone and muscle is studied in biomechanics). Bones protect internal organs, such as the skull protecting the brain or the ribs protecting the heart and lungs. Because of the way that bone is formed, bone has a high compressive strength of about 170 MPa (1,700 kgf/cm2), poor tensile strength of 104–121 MPa, and a very low shear stress strength (51.6 MPa). This means that bone resists pushing (compressional) stress well, resist pulling (tensional) stress less well, but only poorly resists shear stress (such as due to torsional loads). While bone is essentially brittle, bone does have a significant degree of elasticity, contributed chiefly by collagen. Mechanically, bones also have a special role in hearing. The ossicles are three small bones in the middle ear which are involved in sound transduction.
Sources: en.wikipedia.org
=== Logic === Formal logic is used for reasoning and knowledge representation. Formal logic comes in two main forms: propositional logic (which operates on statements that are true or false and uses logical connectives such as "and", "or", "not" and "implies") and predicate logic (which also operates on objects, predicates and relations and uses quantifiers such as "Every X is a Y" and "There are some Xs that are Ys"). Deductive reasoning in logic is the process of proving a new statement (conclusion) from other statements that are given and assumed to be true (the premises). Proofs can be structured as proof trees, in which nodes are labelled by sentences, and children nodes are connected to parent nodes by inference rules. Given a problem and a set of premises, problem-solving reduces to searching for a proof tree whose root node is labelled by a solution of the problem and whose leaf nodes are labelled by premises or axioms. In the case of Horn clauses, problem-solving search can be performed by reasoning forwards from the premises or backwards from the problem. In the more general case of the clausal form of first-order logic, resolution is a single, axiom-free rule of inference, in which a problem is solved by proving a contradiction from premises that include the negation of the problem to be solved. Inference in both Horn clause logic and first-order logic is undecidable, and therefore intractable. However, backward reasoning with Horn clauses, which underpins computation in the logic programming language Prolog, is Turing complete.
His explorations on Pichincha included documenting frequent earthquakes, which led to local rumors attributing the tremors to his presence. Humboldt’s work during this period advanced scientific understanding of high-altitude geology and volcanology.
=== Second line === After at least three months without improvement, extracorporeal shockwave therapy (ESWT) may be considered. Meta-analyses suggest that significant pain relief lasts up to one year after the procedure. However, debate about the therapy's efficacy continued as of 2014. ESWT may involve anesthesia, though studies suggest that anesthesia diminishes the procedure's effectiveness. Complications are rare and typically benign. Known complications include mild hematoma or ecchymosis, redness around the procedure site, or migraine.
Sources: en.wikipedia.org
It corresponds to a fragment of the larger protein prothymosin alpha, which is present in many tissues. The isolated 28-amino-acid peptide was originally obtained from thymus preparations, and the pharmaceutical product is synthesized rather than extracted. The term therefore describes both a natural fragment and a manufactured drug substance.
Thymosin alpha-1 is a single defined 28-residue peptide, while the broader family includes unrelated peptides such as thymosin beta-4. The shared name reflects historical isolation from thymus tissue rather than a common structure. Confusion between the two is common in older literature.
No single pathway fully accounts for its reported effects. Several studies describe interaction with innate immune receptors and downstream cytokine changes, but the complete picture is not settled. Open questions remain about which effects occur at physiological concentrations.
Dry lyophilized powder tolerates short ambient exposure during handling and shipping. Long-term room-temperature storage is not recommended because moisture uptake and slow degradation can occur over months. Storage at minus twenty degrees Celsius is the common practice for extended periods.